Clinical trials: sargramostim, completed
Colorectal Cancer, Kidney Cancer
Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030342
- Testing
- recombinant interferon alfa, sargramostim, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- St. Luke's Medical Center
Carcinoma, Hepatocellular
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
The purpose of this research study is to determine whether JX-594 (Pexa-Vec) has significant anti-tumoral activity and tolerability in primary hepatocellular carcinoma and to determine the dose to be used in further testing.
- Trial name
- NCT00554372
- Testing
- JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Jennerex Biotherapeutics
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
RATIONALE: Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy or…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00053157
- Testing
- sargramostim
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myelogenous Leukemia, Myelodysplasia
Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia
The purpose of this study is to test the safety of a new investigational acute myeloblastic leukemia (AML) vaccine and see what effects (good and bad) it has on patients with advanced myelodysplasia or acute myelogenous leukemia.
- Trial name
- NCT00136422
- Testing
- autologous tumor cells
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying three different doses of a vaccine and comparing them to see how well they work in treating…
- Trial name
- NCT00089219
- Testing
- IFA, 6MHP, GM-CSF
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Virginia
Metastatic Renal Cell Carcinoma
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy…
- Trial name
- NCT01265901
- Testing
- Sunitinib, GM-CSF, Cyclophosphamide
- Where
- 105 sites in United States, France and 9 more
- Volunteers
- 339 people
- Sponsor
- Immatics Biotechnologies GmbH
Autoimmune Pulmonary Alveolar Proteinosis
Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
Autoimmune PAP is a rare lung disease affecting less than 5,000 individuals in US with no FDA-approved pharmacologic therapy. Results from "off-label" use in case reports and clinical studies completed outside of the US indicate…
- Trial name
- NCT03006146
- Testing
- Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Leukemia
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00005962
- Testing
- sargramostim, cyclophosphamide, cytarabine
- Where
- 65 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Drug Kinetics, Drug Effects on Physiology
Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation
This single center, single ascending dose (SAD) and repeat dose study in healthy adults comprises 2 parts. Part 1 will consist of 6 SAD cohorts, in which different dose levels of sargramostim will be given by intravenous (IV)…
- Trial name
- NCT05366283
- Testing
- sargramostim
- Where
- Canada
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Partner Therapeutics, Inc.
Prostatic Neoplasm, Prostate Cancer
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
The main purpose of this study was to determine whether ADT started before or after sipuleucel-T led to a better immune system response.
- Conditions
- Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma
- Trial name
- NCT01431391
- Testing
- sipuleucel-T, leuprolide acetate
- Where
- 14 sites in United States
- Volunteers
- 68 people
- Sponsor
- Dendreon
Lymphoma, Non Hodgkin's Lymphoma
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL
We now propose to investigate the combination of CHOP-Rituxan plus PEG-Filgrastim (PEG-filgrastim) and GM-CSF. PEG-Filgrastim would be given in order to allow us to administer the chemotherapy courses every 2 weeks with the…
- Trial name
- CHOP-R (NCT01527422)
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
- Where
- Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Fernando Cabanillas
Sarcoma, Kaposi, HIV Infections
A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma
To determine the safety as well as the most effective dose of sargramostim (GM-CSF; granulocyte-macrophage colony stimulating factor) that will prevent the side effects caused by the combined use of zidovudine (AZT) and various…
- Trial name
- NCT00000681
- Testing
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prostate Cancer
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
- Trial name
- NCT00901342
- Testing
- sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 104 people
- Sponsor
- Dendreon
Follicular Lymphoma
Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma
The purpose of this study is to compare the safety and immune activity of three doses of tumor vaccine. In recent years, researchers at the Dana-Farber Cancer Institute have discovered that vaccines made from patient's own cancer…
- Trial name
- NCT00487305
- Testing
- Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Leukemia
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
The goal of this clinical research study is to find out if giving a boost of natural killer (NK) cells from a donor combined with Rituxan (rituximab), can help to control disease in patients who have already received an…
- Conditions
- Lymphoma, Leukemia, Transplantation, Stem Cell, Lymphoid Malignancies
- Trial name
- NCT00383994
- Testing
- GM-CSF, Rituximab, NK Cell Infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer
- Trial name
- NCT00436254
- Testing
- pNGVL3-hICD vaccine, sargramostim, flow cytometry
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Washington
Arthritis, Rheumatoid
Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis
This study is designed to explore the activity of granulocyte-macrophage colony stimulating factor (GM-CSF) signaling pathway in subjects with rheumatoid arthritis (RA), the potential impact of inhibition of this axis by…
- Trial name
- NCT02799472
- Testing
- GSK3196165, MTX, Folic (or folinic) acid
- Where
- 16 sites in United States, Germany and 1 more
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline
Severe Acute Respiratory Syndrome (SARS) Pneumonia, COVID-19 Pneumonia
GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia
To assess the safety and tolerability of inhaled molgramostim nebuliser solution in patients with COVID-19 pneumonia.
- Trial name
- GI-COVID (NCT04569877)
- Testing
- Molgramostim nebuliser solution
- Where
- 9 sites in Germany
- Volunteers
- 63 people
- Sponsor
- University of Giessen
Appendicitis Perforated
Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Antibiotics for Perforated Appendicitis
The objective of this trial is to evaluate if intraoperative intraperitoneal administration of fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) followed by oral…
- Trial name
- NCT03435900
- Testing
- Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o., Standard antibiotics intravenously
- Where
- 2 sites in Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
HIV Infections
Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a naturally occurring substance that is made by the body in response to infection or inflammation, and greatly improves cellular immune responses.
- Trial name
- NCT00272493
- Testing
- Hepatitis B virus vaccine with GM-CSF adjuvant, Hepatitis B virus vaccine
- Where
- 11 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)